M&A TRANSACTION · 2020
Human Longevity's Oncology Division acquired by NeoGenomics, Inc.
$37.0M· 3.70x revenue
Target
Human Longevity's Oncology Division
Acquirer
NeoGenomics, Inc.
Strategic buyer
Disclosed financials at time of acquisition
Revenue
$10.0M
EBITDA
—
Deal Value
$37.0M
EV/EBITDA
—
Context
This $37.0M acquisition of Human Longevity's Oncology Division by NeoGenomics, Inc. sits in the medical practice specialty sub-vertical. NeoGenomics, Inc. is acquiring as a strategic buyer; see how strategic acquirers typically price medical practice specialty businesses on our Medical Practice Specialty strategic buyer-pool page.
Source
Data sourced from Press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology
Value your own medical practice specialty
Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.
Compare your business to the Human Longevity's Oncology Division acquisition.